Bioxytran (BIXT) Change in Receivables (2012 - 2018)
Bioxytran (BIXT) posted Change in Receivables of $2761.0 for Q2 2018, up 113.2% sequentially from -$20920.0 in Q1 2018.
Bioxytran (BIXT) Change in Receivables (2012 - 2018) Analysis & Trends
Bioxytran has reported Change in Receivables for 7 years, with the latest figure at $2761.0 in Q2 2018.
- Quarterly Change in Receivables changed N/A year-over-year to $2761.0 in Q2 2018, while the trailing twelve-month figure through Jun 2018 was $4800.0 (up 109.83% YoY) and the FY2017 annual result came in at $13359.0, up 39.16% from the prior year.
- Change in Receivables advanced to $2761.0 in Q2 2018 per BIXT's latest filing, from -$20920.0 in the prior quarter.
- Over five years, Change in Receivables peaked at $60828.0 in Q1 2014 and troughed at -$28058.0 in Q2 2014.
- A 5-year average of $105.62 and a median of -$12035.0 in 2014 frame the typical range for Change in Receivables.
- The sharpest annual moves came in 2014 and 2015: Change in Receivables plunged 1282.85% in 2014, then soared 235.52% in 2015.
- Over 5 years, Change in Receivables stood at -$12035.0 in 2014, then tumbled by 54.55% to -$18600.0 in 2015, then dropped by 10.97% to -$20640.0 in 2016, then soared by 35.51% to -$13310.0 in 2017, then jumped by 120.74% to $2761.0 in 2018.
- According to Business Quant data, Change in Receivables over the past three periods registered $2761.0, -$20920.0, and -$13310.0 for Q2 2018, Q1 2018, and Q4 2017 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.81 Bn | 130.96 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 86.07 Bn | 78.08 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 65.47 Bn | 60.29 Bn | 1.37 Bn | - |
| 4 | Moderna | 55.64 Bn | 50.50 Bn | 52.00 Mn | -53.00 Mn |
| 5 | BeOne Medicines | 41.99 Bn | 36.89 Bn | 1.53 Bn | 117.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.68 Bn | 28.37 Bn | 992.69 Mn | 31.60 Mn |
| 7 | BioNTech SE | 27.69 Bn | 9.29 Bn | 668.28 Mn | 94.29 Mn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 37.16 Mn |
| 9 | Royalty Pharma | 27.36 Bn | 26.52 Bn | - | - |
| 10 | Bioxytran | 2.52 Mn | 2.27 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2018 | 2,761.00 |
| Jun 30, 2018 | 2,761.00 |
| Mar 31, 2018 | -20,920.00 |
| Mar 31, 2018 | -20,920.00 |
| Dec 31, 2017 | -13,310.00 |
| Dec 31, 2017 | -13,310.00 |
| Sep 30, 2017 | 36,269.00 |
| Sep 30, 2017 | 36,269.00 |
| Mar 31, 2017 | -9,600.00 |
| Mar 31, 2017 | -9,600.00 |
| Dec 31, 2016 | -20,640.00 |
| Dec 31, 2016 | -20,640.00 |
| Sep 30, 2015 | -18,600.00 |
| Sep 30, 2015 | -18,600.00 |
| Jun 30, 2015 | 38,025.00 |
| Jun 30, 2015 | 38,025.00 |
| Mar 31, 2015 | 2,317.00 |
| Mar 31, 2015 | 2,317.00 |
| Dec 31, 2014 | -12,035.00 |
| Dec 31, 2014 | -12,035.00 |